ES004 / Elpiscience - LARVOL DELTA

A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response. (PubMed, Antib Ther) - "Unlike CD47-targeted agents, ES004-B5 exhibits an excellent safety profile in nonhuman primates. ES004-B5 has potential to be an important backbone for SIRPα-based combination therapy and/or bispecific antibodies, which will likely overcome the limitations of CD47-targeted agents encountered in clinical settings."

IO biomarker • Journal • Oncology • CD47 • SIRPA

Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity (SITC 2022) - "Through blocking CD47-induced inhibitory “don’t eat me” signals, ES004-B5 potently potentiates ADCP activity of anti-TAA antibodies like rituximab and cetuximab. Conclusions In summary, the functional anti-SIRPα mAb ES004-B5 has great potential to be used in combinations with multiple anti-TAA antibodies in cancer treatment. We are currently advancing the development of ES004-B5 into clinical candidate."

Combination therapy • Oncology • CD47 • CLDN18 • CLDN8 • SIRPA

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting....Abstract No.: 793...Highlights: (i) ES004 potently blocks CD47-SIRPα interaction and CD47 induced SIRPα signaling; (ii) ES004 effectively potentiates pan-allelic macrophage phagocytosis of tumor cells; (iii) ES004 has no negative impact on T cell activation; (iv) ES004 enhances anti-tumor activity in combination with anti-Claudin18.2 in MC38/hCLDN18.2 syngenetic tumor model; (v) ES004 has demonstrated favorable PK, full target occupancy and excellent safety profile in cynomolgus monkeys."

Preclinical • Oncology • Solid Tumor

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019."

Preclinical • Oncology